This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Severini, A.
Right arrow Articles by Tyrrell, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Severini, A.
Right arrow Articles by Tyrrell, D. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 07 1995, 1430-1435, Vol 39, No. 7
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)- beta-L-2',3'-dideoxy-3'-thiacytidine

A Severini, XY Liu, JS Wilson and DL Tyrrell
Glaxo Heritage Research Institute, Department of Medical Microbiology and Infectious Diseases, University of Alberta, Edmonton, Canada.

We have used the endogenous reverse transcriptase reaction of viral core particles from duck liver to elucidate the mechanism of inhibition of duck hepatitis B virus (DHBV) replication by the nucleoside analog (- )-beta-L-2',3'-dideoxy-3'-thiacytidine (3TC). As is the case in human immunodeficiency virus replication, 3TC-5'-triphosphate (3TC-TP) acts as a chain terminator for the DNA polymerase activities. The results of several different experiments support this conclusion, which explains the potent activity of 3TC against the hepadnaviruses. In isolated DHBV core particles, 3TC-TP inhibited the reverse transcriptase in a manner that resembled competitive inhibition with respect to dCTP. However, the kinetics of inhibition was not linear on a double-reciprocal plot for the highest concentrations of 3TC-TP and the lowest concentration of dCTP. This anomaly would be expected if binding to the nucleotide site was followed by DNA chain termination. Calculations that used only the linear part of the curve yielded a Ki of 0.78 +/- 0.10 microM 3TC- TP. The inhibition of core particles incubated in vitro with 3TC-TP was not reversed by removal of the free inhibitor. 3TC-TP inactivated the reverse transcriptase activity in a concentration-dependent manner. The Km of the chain termination reaction was calculated at 0.71 +/- 0.05 microM. Similar competitive kinetics and irreversible inhibition were also obtained on the endogenous DNA polymerase from viral particles from serum, suggesting that 3TC-TP also acts as a chain terminator of the DNA-directed DNA polymerase of DHBV replication.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:

  • Tchesnokov, E. P., Obikhod, A., Schinazi, R. F., Gotte, M. (2008). Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase. J. Biol. Chem. 283: 34218-34228 [Abstract] [Full Text]  
  • Zimmerman, K. A., Fischer, K. P., Joyce, M. A., Tyrrell, D. L. J. (2008). Zinc Finger Proteins Designed To Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue Culture. J. Virol. 82: 8013-8021 [Abstract] [Full Text]  
  • Pallier, C., Castera, L., Soulier, A., Hezode, C., Nordmann, P., Dhumeaux, D., Pawlotsky, J.-M. (2006). Dynamics of Hepatitis B Virus Resistance to Lamivudine. J. Virol. 80: 643-653 [Abstract] [Full Text]  
  • Lindstrom, A., Odeberg, J., Albert, J. (2004). Pyrosequencing for Detection of Lamivudine-Resistant Hepatitis B Virus. J. Clin. Microbiol. 42: 4788-4795 [Abstract] [Full Text]  
  • Iyer, R. P., Jin, Y., Roland, A., Morrey, J. D., Mounir, S., Korba, B. (2004). Phosphorothioate Di- and Trinucleotides as a Novel Class of Anti-Hepatitis B Virus Agents. Antimicrob. Agents Chemother. 48: 2199-2205 [Abstract] [Full Text]  
  • Walters, K.-A., Tipples, G. A., Allen, M. I., Condreay, L. D., Addison, W. R., Tyrrell, L. (2003). Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening. Antimicrob. Agents Chemother. 47: 1936-1942 [Abstract] [Full Text]  
  • Kimura, T., Rokuhara, A., Matsumoto, A., Yagi, S., Tanaka, E., Kiyosawa, K., Maki, N. (2003). New Enzyme Immunoassay for Detection of Hepatitis B Virus Core Antigen (HBcAg) and Relation between Levels of HBcAg and HBV DNA. J. Clin. Microbiol. 41: 1901-1906 [Abstract] [Full Text]  
  • Abdelhamed, A. M., Kelley, C. M., Miller, T. G., Furman, P. A., Cable, E. E., Isom, H. C. (2003). Comparison of Anti-Hepatitis B Virus Activities of Lamivudine and Clevudine by a Quantitative Assay. Antimicrob. Agents Chemother. 47: 324-336 [Abstract] [Full Text]  
  • Yamamoto, T., Litwin, S., Zhou, T., Zhu, Y., Condreay, L., Furman, P., Mason, W. S. (2002). Mutations of the Woodchuck Hepatitis Virus Polymerase Gene That Confer Resistance to Lamivudine and 2'-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyluracil. J. Virol. 76: 1213-1223 [Abstract] [Full Text]  
  • Delaney, W. E. IV, Edwards, R., Colledge, D., Shaw, T., Torresi, J., Miller, T. G., Isom, H. C., Bock, C. T., Manns, M. P., Trautwein, C., Locarnini, S. (2001). Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus. Antimicrob. Agents Chemother. 45: 1705-1713 [Abstract] [Full Text]  
  • Whalley, S. A., Brown, D., Teo, C. G., Dusheiko, G. M., Saunders, N. A. (2001). Monitoring the Emergence of Hepatitis B Virus Polymerase Gene Variants during Lamivudine Therapy Using the LightCycler. J. Clin. Microbiol. 39: 1456-1459 [Abstract] [Full Text]  
  • Schalm, S W, Heathcote, J, Cianciara, J, Farrell, G, Sherman, M, Willems, B, Dhillon, A, Moorat, A, Barber, J, Gray, D F, International Lamivudine Study Group, (2000). Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46: 562-568 [Abstract] [Full Text]  
  • Stuyver, L., Van Geyt, C., De Gendt, S., Van Reybroeck, G., Zoulim, F., Leroux-Roels, G., Rossau, R. (2000). Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy. J. Clin. Microbiol. 38: 702-707 [Abstract] [Full Text]  
  • Le Guerhier, F., Pichoud, C., Guerret, S., Chevallier, M., Jamard, C., Hantz, O., Li, X.-Y., Chen, S.-H., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F. (2000). Characterization of the Antiviral Effect of 2',3'-Dideoxy-2', 3'-Didehydro-beta -L-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model. Antimicrob. Agents Chemother. 44: 111-122 [Abstract] [Full Text]  
  • Sarafianos, S. G., Das, K., Clark, A. D. Jr., Ding, J., Boyer, P. L., Hughes, S. H., Arnold, E. (1999). Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta -branched amino acids. Proc. Natl. Acad. Sci. USA 96: 10027-10032 [Abstract] [Full Text]  
  • Seifer, M., Hamatake, R. K., Colonno, R. J., Standring, D. N. (1998). In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir. Antimicrob. Agents Chemother. 42: 3200-3208 [Abstract] [Full Text]  
  • Zhu, Y.-L., Dutschman, G. E., Liu, S.-H., Bridges, E. G., Cheng, Y.-C. (1998). Anti-Hepatitis B Virus Activity and Metabolism of 2',3'-Dideoxy-2',3'-Didehydro-beta -L(-)-5-Fluorocytidine. Antimicrob. Agents Chemother. 42: 1805-1810 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»